Biomarkers.

Background: Connectome-based models of disease propagation are used to probe mechanisms of pathology spread in neurodegenerative disease. We present our network spreading model toolbox that allows the user to compare model fits across different models and parameters. We apply the toolbox to assess whether local amyloid levels affect production of pathological tau.

Developing Topics.

Background: Neurotransmitter receptors' contribution to Alzheimer's disease (AD) pathology development has been implicated by basic science studies but is yet to be fully established. Here, we incorporate receptor density maps into network spreading models to predict amyloid and tau patterns in AD, reflecting their potential roles in facilitating or impeding pathology production and connectivity-mediated spread.

Method: Amyloid-PET positive individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were divided into "early" (n = 119) and "late" (n = 69) pathology groups according to tau accumulation in the temporal cortex (Figure 1A).

Alzheimer's Imaging Consortium.

Background: Connectome-based models of disease propagation are used to probe mechanisms of pathology spread in neurodegenerative disease. We present our network spreading model toolbox that allows the user to compare model fits across different models and parameters. We apply the toolbox to assess whether local amyloid levels affect production of pathological tau.

Oral cavity and oropharyngeal cancers in Texas: examining incidence rates in dental health professional shortage areas.

Purpose: Oral cavity (OC) and oropharyngeal (OP) cancer rates have increased annually rising in the U.S. and Texas.

The role of brainstem biopsy and targeted therapies in pediatric diffuse midline glioma/diffuse intrinsic pontine glioma.

Pediatric diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), are aggressive brainstem tumors with a dire prognosis, traditionally diagnosed based on MRI characteristics. The recognition that molecular characteristics may determine prognosis and response to therapy has led to a reevaluation of biopsy necessity. This comprehensive review addresses the evolving role of brainstem biopsies in diagnosing and managing these tumors - both within the context of a clinical trial and in routine clinical care.